<SEC-DOCUMENT>0001144204-16-086190.txt : 20160304
<SEC-HEADER>0001144204-16-086190.hdr.sgml : 20160304
<ACCEPTANCE-DATETIME>20160304171545
ACCESSION NUMBER:		0001144204-16-086190
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20160304
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160304
DATE AS OF CHANGE:		20160304

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cellectar Biosciences, Inc.
		CENTRAL INDEX KEY:			0001279704
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043321804
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36598
		FILM NUMBER:		161486159

	BUSINESS ADDRESS:	
		STREET 1:		3301 AGRICULTURE DRIVE
		CITY:			MADISON
		STATE:			WI
		ZIP:			53716
		BUSINESS PHONE:		617-244-1616

	MAIL ADDRESS:	
		STREET 1:		3301 AGRICULTURE DRIVE
		CITY:			MADISON
		STATE:			WI
		ZIP:			53716

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVELOS THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050617

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COMMON HORIZONS INC
		DATE OF NAME CHANGE:	20040211
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v433496_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B><BR>
<B>SECURITIES AND EXCHANGE COMMISSION</B><BR>
Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">___________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">___________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report: March 4, 2016<BR>
(<I>Date of earliest event reported</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CELLECTAR BIOSCIENCES, INC.</B><BR>
(<I>Exact name of registrant as specified in its charter</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; padding-right: 0.2in; padding-left: 0.2in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Delaware</B></P></TD>
    <TD STYLE="width: 34%; padding-right: 0.2in; padding-left: 0.2in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>1-36598</B></P></TD>
    <TD STYLE="width: 33%; padding-right: 0.2in; padding-left: 0.2in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>04-3321804</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(State or other jurisdiction</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>of incorporation)</I></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Commission</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>File Number)</I></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(IRS Employer</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Identification Number)</I></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3301 Agriculture Drive </B><BR>
<B>Madison, WI 53716</B><BR>
(<I>Address of principal executive offices</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(608) 441-8120</B><BR>
(<I>Registrant's telephone number, including area code</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>ITEM 5.03</B></TD><TD STYLE="text-align: justify"><B>AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective at the close of business on March 4, 2016, we amended
our second amended and restated certificate of incorporation to effect a 1-for-10 reverse split of our common stock (the &ldquo;Reverse
Split&rdquo;). Immediately following the effectiveness of the Reverse Split, there were approximately 858,140 shares of our common
stock outstanding. Stockholders will receive a cash payment in lieu of any issuance of fractional shares. The number of shares
of common stock issuable upon exercise or conversion of all outstanding options, warrants and convertible debt and the associated
exercise or conversion prices will be adjusted accordingly for the Reverse Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At our special meeting of stockholders held on February 8, 2016,
our stockholders approved an amendment to our certificate of incorporation that would effect a reverse split of our common stock
at a ratio between 1:5 to 1:10 to be determined by the board of directors in its. Our stockholders further authorized the board
of directors to determine the ratio at which the reverse split would be effected by filing an appropriate amendment to our certificate
of incorporation. Our board of directors authorized the ratio of the Reverse Split on February 24, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the amendment to our certificate of incorporation
is attached as Exhibit 3.1 and is incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>ITEM 7.01</B></TD><TD STYLE="text-align: justify"><B>REGULATION FD DISCLOSURE</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 4, 2016, we issued a press release announcing the Reverse
Split. A copy of the press release is furnished as Exhibit 99.1, and is incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>ITEM 9.01</B></TD><TD STYLE="text-align: justify"><B>FINANCIAL STATEMENTS AND EXHIBITS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Number</FONT></TD>
    <TD STYLE="width: 2%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 86%; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Title</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of Cellectar Biosciences, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Press release dated March 4, 2016, entitled &ldquo;Cellectar Biosciences Announces 1-for-10 Reverse Stock Split&rdquo;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">SIGNATURE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">Dated:&nbsp;&nbsp;March 4, 2016</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><B>CELLECTAR BIOSCIENCES, INC.</B></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 50%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 3%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 27%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 20%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">By: </TD>
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid"><I>/s/&nbsp;&nbsp;Chad J. Kolean</I></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Name:&nbsp;&nbsp;Chad J. Kolean </TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">Title:&nbsp;&nbsp;Vice President and Chief Financial Officer</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Number</FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 86%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Title</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of Cellectar Biosciences, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Press release dated March 4, 2016, entitled &ldquo;Cellectar Biosciences Announces 1-for-10 Reverse Stock Split&rdquo;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>v433496_ex3-1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 3.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATE OF AMENDMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECOND AMENDED AND RESTATED CERTIFICATE
OF INCORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CELLECTAR BIOSCIENCES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>CELLECTAR BIOSCIENCES, INC.</B> (the
&ldquo;Corporation&rdquo;), a corporation organized and existing under of the General Corporation Law of the State of Delaware,
does hereby certify:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>FIRST</B>: The name of the Corporation
is Cellectar Biosciences, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECOND</B>: The Second Amended and Restated
Certificate of Incorporation of the Corporation is hereby amended by inserting the following paragraphs in Article FOURTH thereof
immediately following the first paragraph of said Article FOURTH:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;Upon
the effectiveness of the amendment to the Second Amended and Restated Certificate of Incorporation adding this paragraph thereto
(the &ldquo;Effective Time&rdquo;), each share of Common Stock, par value $0.00001 per share issued and outstanding immediately
prior to the Effective Time (the &ldquo;Original Common Stock&rdquo;), shall be reclassified into 1/10 of a share of Common Stock,
such Common Stock to have the rights and powers set forth in the Certificate of Incorporation and under the General Corporation
Law of the State of Delaware (the &ldquo;Reclassification&rdquo;). All shares of Common Stock issued to any holder of Original
Common Stock as a result of the Reclassification shall be aggregated for the purpose of determining the number of shares of Common
Stock to which such holder shall be entitled, and no fractional shares shall be issued in connection with the Reclassification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Any stockholder
who would otherwise be entitled to receive a fractional share of Common Stock as a result of the Reclassification shall receive
in lieu thereof cash in an amount equal to such fraction multiplied by the fair market value of one share of Common Stock, based
on the average of the high and low bid prices of the Common Stock as quoted on Nasdaq on the last trading day immediately preceding
the Effective Time. No cash in lieu of any fractional share shall be paid to any stockholder until such stockholder shall have
surrendered for transfer or otherwise accounted to the Corporation for the outstanding stock certificates entitling such stockholder
to such cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">At and after
the Effective Time, outstanding certificates that prior thereto represented shares of Original Common Stock shall be deemed for
all purposes to evidence ownership of and to represent that number of shares of Common Stock into which the shares previously represented
by such certificates have been reclassified as herein provided (and the right to receive cash in lieu of any fraction of a share
as provided herein). Until any such outstanding stock certificates have been surrendered for transfer or otherwise accounted for
to the Corporation, the registered owner thereof on the books and records of the Corporation shall have and be entitled to exercise
any voting and other rights with respect to, and receive any dividend and other distributions upon, the shares of Common Stock
issued in respect of the Original Common Stock formerly evidenced by such certificates.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>THIRD</B>: The foregoing amendment was
duly adopted in accordance with the provisions of Section&nbsp;242 of the General Corporation Law of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>FOURTH</B>: The foregoing amendment shall
be effective at 5:00 pm eastern time on March 4, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the Corporation has
caused this Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation to be signed by James Caruso,
its President and Chief Executive Officer, thereto duly authorized, this 26<SUP>th</SUP> day of February, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"><FONT STYLE="text-transform: uppercase"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="text-transform: uppercase">CELLECTAR BIOSCIENCES, Inc.</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 45%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 3%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 47%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 5%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">By:</TD>
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid"><I>/s/ James Caruso</I></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">James Caruso</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">President and Chief Executive Officer</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>v433496_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: right; text-indent: 0in"><B>Exhibit
99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: 0in"><B>Cellectar
Biosciences Announces 1-for-10 Reverse Stock Split</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MADISON, WI (March 4, 2016)</B> &ndash;
Cellectar Biosciences, Inc. (NASDAQ: CLRB), an oncology-focused biotechnology company, today announces a 1-for-10 reverse stock
split of its common stock, effective at the close of business today.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shares of Cellectar&rsquo;s common stock
will trade on a post-split basis beginning on March&nbsp;7, 2016. The Company&rsquo;s ticker symbol, CLRB, will remain unchanged.
The new CUSIP number for Cellectar&rsquo;s common stock post-reverse stock split will be 15117F302.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We believe there are important benefits
for our company resulting from this reverse stock split. In addition to supporting our continuing efforts to remain listed on NASDAQ,
which, among other things, requires our stock be at a bid price of $1.00 or higher, we believe the reverse stock split will better
position the company to attract capital in future financing transactions,&rdquo; said Jim Caruso, president and CEO of Cellectar.
&ldquo;With a focused investment of additional capital to drive our clinical and research programs, we believe there is a significant
opportunity to create meaningful stockholder value.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the effective time of the reverse stock
split, every 10 shares of Cellectar&rsquo;s issued and outstanding common stock will automatically be combined into 1 issued and
outstanding share of common stock without any change in the par value of the shares. This will reduce the number of outstanding
common shares of Cellectar from approximately 8.6 million to approximately 860,000. Stockholders approved the reverse split at
the Special Meeting held on February 8, 2016. Additional information can be found in a Form 8-K to be filed with the Securities
and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Proportionate voting rights and other rights
of common stockholders will not be affected by the reverse stock split, other than as a result of the cashing out of fractional
shares. Stockholders who would otherwise hold a fractional share of common stock will receive a cash payment in lieu of a fractional
share. Please direct any questions you might have regarding payments for fractional shares to your broker or the company&rsquo;s
stock transfer agent, American Stock Transfer &amp; Trust Company, by calling (718) 921-8317.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Cellectar Biosciences, Inc.</B><BR>
Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse
oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC platform is based on the company's proprietary
phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range
of cancers. Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The Company's
lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 is currently being evaluated
under an orphan drug designated Phase 1 study in patients with relapsed or refractory multiple myeloma. The company is also developing
PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1602-PTX), a preclinical stage product candidate, and plans
to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&amp;D efforts. For additional information
please visit www.cellectarbiosciences.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"># # #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This news release contains forward-looking
statements. You can identify these statements by our use of words such as &quot;may,&quot; &quot;expect,&quot; &quot;believe,&quot;
&quot;anticipate,&quot; &quot;intend,&quot; &quot;could,&quot; &quot;estimate,&quot; &quot;continue,&quot; &quot;plans,&quot; or
their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and
uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements
are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree
of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise
additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification
of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and
other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates,
competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks
and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission
including our Form 10-K/A for the year ended December&nbsp;31, 2014. These forward-looking statements are made only as of the date
hereof, and we disclaim any obligation to update any such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><BR>
<BR>
INVESTOR AND MEDIA CONTACT:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Jules Abraham<BR>
JQA Partners<BR>
917-885-7378</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">jabraham@jqapartners.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !* 1<# 2(  A$! Q$!_\0
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M;ZXPTG4D&)8;KY%)[E'/RLI[$&I&\::9<745II'F:M<2. 5M!E(USRS.?E
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MM/=MEBMY&#P]M(#G\#@_I7T-1772QM6FK;KS$XH^9/\ A#O$V[;_ &!J.?\
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MYR?4+&9:^']*L[A;B&T7SD^X[NSE?IN)Q^%:=%%)MO< HHHI %%%% !1110
&4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
